替比夫定治疗HBeAg阳性慢性乙型肝炎的效果观察

目的观察替比夫定治疗HBeAg阳性慢性乙型肝炎的效果。方法回顾性分析2010年2月～2012年2月于沈阳市第六人民医院传染科治疗的HBeAg阳性慢性乙型肝炎患者104例的临床资料。将采用替比夫定治疗的52例患者作为替比夫定组,将采用拉米夫定治疗的52例患者作为拉米夫定组,观察并比较两组治疗12、24、52周ALT复常、HBV DNA转阴、HBeAg血清学转换情况。结果治疗12周,两组ALT复常率、HBV DNA转阴率及HBeAg血清学转换率,差异均无统计学意义（P〉0.05）;治疗24周时,替比夫定组HBeAg血清学转换率（13.5%）高于拉米夫定组（5.8%）,差异有统计学意义（P〈0.05）;治疗52周时,替比夫定组ALT复常率、HBV DNA转阴率及HBeAg血清学转换率均高于拉米夫定组,差异均有统计学意义（P〈0.05）。结论采用替比夫定治疗HBeAg阳性慢性乙型肝炎的效果较好,安全性较高,值得临床推广应用。

Effect observation of telbivudine in the treatment of HBeAg-positive chronic hepatitis B

Objective To observe the effect of telbivudine in the treatment of HBeAg -positive chronic hepatitis B. Methods Clinical data of 104 patients with HBeAg-positive chronic hepatitis B treated in infectious disease department of the 6th people＇s hospital of Shenyang City from February 2010 to February 2012 were analyzed retrospectively. 52 patients treated with telbivudine were selected as the telbivudine group, 52 patients treated with lamivudine were selected as the lamivudine group. 12, 24, 52 weeks after treatment, the serum ALT normalization rate, HBV DNA negative rate and HBeAg serological conversion rate of the two groups were observed and compared. Results Twelve weeks after treatment, the serum ALT normalization rates, HBV DNA negative rates and HBeAg serological conversion rates between the telbivudine group and the lamivudine group had no significant differences （P 0.05）. 24 weeks after treatment, the HBeAg serological conversion rates in telbivudine group （13.5%） was highter than the lamivudine group （5.8%）, had significant differences （P 0.05）. 52 weeks after treatment, the serum ALT normalization rate, HBV DNA negative rate and HBeAg serological conversion rate in the telbivudine group were all significantly higher than those in the lamivudine group （P 0.05）. Conclusion The effect of telbivudine in the treatment of HBeAg-positive chronic hepatitis B is better, which is also a safety method for treatment, it is worthy of clinical application.